About Beactica
Beactica is a company based in Uppsala (Sweden) founded in 2006. Beactica offers products and services including Eclipsor™ Synthetic Lethality Platform. Beactica operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
- Headquarter Uppsala, Sweden
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Beactica Therapeutics Ab
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$2.96 M (USD), Grant
Feb 17, 2026
-
Investors
European Union
& 7 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Beactica
Beactica offers a comprehensive portfolio of products and services, including Eclipsor™ Synthetic Lethality Platform.
Platform for identifying synthetic lethality in targeted cancer therapies
People of Beactica
Unlock access to complete
Funding Insights of Beactica
Investors in Beactica
Beactica has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union, Vinnova and Uppsala University.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple sectors are invested in by corporate-backed Almi Invest.
|
Locked | Locked | Locked | |
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked | |
|
Venture capital funding is provided to Swedish companies across sectors.
|
Locked | Locked | Locked |
Investor details for Beactica
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Beactica
Investment portfolio details for Beactica
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Beactica
Detailed financials for Beactica
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Beactica Comparisons
Peer comparison for Beactica
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Beactica
Beactica operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
Detailed competitors of Beactica
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Beactica
Complete news archive for Beactica
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Beactica
Beactica was founded in 2006 and raised its 1st funding round 3 years after it was founded.
Beactica is headquartered in Uppsala, Sweden. It is registered at Uppsala, Uppsala County, Sweden.
Beatica develops small molecule drug discovery platforms. Its proprietary platform is based on surface plasmon resonance and is designed to predict molecule - target interaction, especially when protein crystallization is not possible. The company offers lead optimization and other drug discovery services to pharma companies and research organizations. In addition, Beatica is planning to develop an internal pipeline of its own molecules as well.
Beactica's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Beactica offers Eclipsor™ Synthetic Lethality Platform.
Beactica has 8 investors. Key investors include European Union, Vinnova, Uppsala University, Unionen, and Almi Invest.